Bristol-Myers Hepatitis C Combo Therapy Shows Promise
This article is for subscribers only.
Bristol-Myers Squibb Co., which took a $1.8 billion charge in the third quarter after ending work on a drug for hepatitis C, may have hope for a new regimen shown to clear the liver infection from patients in a study.
Results from a 16-patient trial presented today at the American Association for the Study of Liver Diseases in Boston showed that combining three of the company’s experimental medicines, daclatasvir, asunaprevir and BMS-791325, cleared the hepatitis C virus in 94 percent of patients. Bristol-Myers plans to take the therapy into final-stage trials in 2014.